Ranjan Kachru - Academia.edu (original) (raw)

Papers by Ranjan Kachru

Indian heart journal, 2008

OBJECTIVE GENAMI, an angiographic follow-up study was undertaken to evaluate the safety and effic... more OBJECTIVE GENAMI, an angiographic follow-up study was undertaken to evaluate the safety and efficacy of a new generation endothelial progenitor cell (EPC) capture stent, GENOUS during primary angioplasty for ST-elevation myocardial infarction (MI). METHODS Eleven consecutive patients with acute ST-elevation MI underwent primary percutaneous coronary intervention (PCI) using a bio-engineered GENOUS EPC stent. RESULTS Procedural success was 100%. Ten patients who survived underwent a follow-up angiography at 8 months. There was no instance of stent thrombosis during the follow-up period up to 12 months. The quantitative angiographic (quantitative coronary analysis [QCA]) follow-up data showed a late loss at 8 months of 0.97 +/- 0.94 mm and the late loss index was 44.35 +/- 40.47% with angiographic restenosis seen in 5 of 10 patients (50%). One of these patients with provocable ischemia underwent repeat PCI. CONCLUSIONS The QCA data of this study shows a high late loss with frequent an...

Diffuse pulmonary arteriovenous fistulae are rare, more so when unilateral. This article describe... more Diffuse pulmonary arteriovenous fistulae are rare, more so when unilateral. This article describes a 12-year-old boy with diffuse right-sided pulmonary arteriovenous fistula in whom prior percutaneous transcatheter coil occlusion has been attempted without success.The patient was subjected to ligation and transection of the right pulmonary artery and he is presently doing well.

Indian Journal of Clinical Cardiology

A 66-year-old diabetic, hypertensive, and hypothyroid female presented in the emergency departmen... more A 66-year-old diabetic, hypertensive, and hypothyroid female presented in the emergency department with cardiac arrest, for which cardiopulmonary resuscitation was immediately initiated. She had been on oral fexofenadine for 36 h prior to the event. Post successful resuscitation, her cardiac rhythm showed high-grade atrioventricular block. Patient was treated with mechanical ventilatory support and temporary transvenous pacing. No treatable cause could be identified, and she recovered completely following fexofenadine discontinuation, without need for a permanent pacemaker. She has remained asymptomatic during 1 year of follow-up with no documented arrhythmias. An electrophysiological study at 6 months revealed prolonged HV interval (70 ms) with 1:1 AV conduction and no inducible arrhythmias. This is probably the first reported case of fexofenadine-induced cardiac arrest in a patient without previous history of heart disease.

Diabetes

Saroglitazar, a dual PPAR α/γ agonist, is approved in India for the treatment of diabetic dyslipi... more Saroglitazar, a dual PPAR α/γ agonist, is approved in India for the treatment of diabetic dyslipidemia (DD) not controlled with statins. DD is highly atherogenic as it is associated with high triglycerides (TG), high small dense LDL (sdLDL) and low HDL-C. In this, prospective multi-centric study conducted in patients with type 2 diabetes and triglycerides (TG) ≥200 mg/dL after lifestyle and stable statin therapy for at least 3 months, efficacy and safety of saroglitazar has been evaluated. Total 104 patients (78% male) with mean age of 59.1 ± 11.4 years were enrolled. All subjects were given saroglitazar 4mg once daily for 24 weeks. The effects of saroglitazar were evaluated at 24 weeks by using paired t-test. Six months follow-up data is available from 73 patients. At 24 weeks the primary end point showed a significant reduction in non-HDL-C (from 138 ± 51 mg/dL to 113 ± 44 mg/dL; p Disclosure U. Kaul: None. P. Jain: None. R. Kachru: None. V. Bhatia: None. P. Arambam: None. S. Shekhawat: None. Y. Diana: None. K. Rawat: None. S. Singh: None. A. Jaiswal: Employee; Self; Zydus Cadila.

Journal of Diabetes & Metabolism

Objective: Diabetic dyslipidemia is highly atherogenic as it is associated with high triglyceride... more Objective: Diabetic dyslipidemia is highly atherogenic as it is associated with high triglyceride (TG), high small dense low-density lipoprotein (sd-LDL) particles and low High-Density Lipoprotein Cholesterol (HDL-C). Saroglitazar, a dual peroxisome proliferator activated receptor agonist (predominant PPAR-α agonist and modest PPAR-γ agonist), is approved in India for the management of diabetic dyslipidemia. The GLIDDER study was done to evaluate the effects of Saroglitazar 4 mg on non HDL-C as the primary endpoint and sd-LDL particles as a secondary endpoint in diabetic patients with dyslipidemia. Methods: This study was a 24 weeks, prospective, multicentre, single arm study conducted in 104 patients with diabetic dyslipidemia (TG ≥ 200 mg/dL) inadequately controlled with diet, exercise, and statins. It was conducted from April 2015 to November 2017 at three Indian centres. All the selected patients were given Saroglitazar 4 mg once daily before breakfast for 24 weeks. Efficacy evaluations of non HDL-C (calculated as Total Cholesterol (TC) minus HDL-C) (primary endpoint) and other lipid parameters (sd-LDL particles, TC, TG, HDL-C) and glycemic parameters (glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG)) were conducted after 24 weeks and compared to the baseline levels. Results: Total 104 patients (22% female) with mean age of 59.1 ± 11.4 years were enrolled in this study. In the perprotocol population, there was a significant reduction in non HDL-C (from 142.3 ± 59.3 mg/dL (baseline) to 109.9 ± 45.5 mg/dL (week-24); p<0.0001) and sd-LDL (from 32.5 ± 11.3 mg/dL (baseline) to 25.9 ± 11.8 mg/dL (week-24); p<0.0001). There was a significant reduction in TG, TC, HbA1c, and FPG with a significant increase in HDL-C at week-24 from baseline levels (p<0.05). Conclusion: Saroglitazar effectively reduces non HDL-C and sd-LDL particles in patients with diabetic dyslipidemia.

Journal of the American College of Cardiology

Indian Heart Journal, 2015

A 35-year-old female presented to emergency room with chest pain of 1-h duration. ECG showed ST e... more A 35-year-old female presented to emergency room with chest pain of 1-h duration. ECG showed ST elevation in V2-V6. She was immediately taken up for primary PCI. Coronary angiography showed diffuse narrowing in distal left anterior descending (LAD) artery with a discrete filling defect suggestive of thrombus. The left circumflex (LCX) and the right coronary arteries (RCA) had no significant abnormalities (Fig. 1). Detailed history revealed that she was having episodic chest pain at rest for the past one year, which was not related to exertion. She had no history of smoking, hypertension, diabetes mellitus, dyslipidemia, family history of premature coronary artery disease, or any substance abuse. She had been

Journal of Vascular and Interventional Radiology, 2006

International Journal of Cardiology, 2007

The American Journal of Cardiology, 2013